-- GlaxoSmithKline, Global Payments, Halozyme: U.S. Equity Preview
-- B y   I n y o u n g   H w a n g
-- 2010-10-12T04:00:03Z
-- http://www.bloomberg.com/news/2010-10-11/glaxosmithkline-global-payments-halozyme-u-s-equity-preview.html
Shares of the following companies
may have unusual moves in U.S. trading. Stock symbols are in
parentheses.       Deere & Co.  (DE US): The world’s largest farm-equipment
maker said sales in September for the utility tractor industry
fell 11 percent, while Deere’s sales were down less than 10
percent. Four-wheel drive tractor sales rose by 17 percent
industrywide, while Deere’s sales gained less than 10 percent,
the company said.  GlaxoSmithKline Plc  (GSK US): The drugmaker’s Hycamtin,
approved by U.S. regulators in 1996 for ovarian cancer, can be
toxic to bone marrow when added to the most common initial
chemotherapy for advanced cases of the disease, according to a
study published online by The Journal of the National Cancer
Institute.       Global Payments Inc.  (GPN US): The provider of card-
processing services reported first-quarter earnings excluding
some items of 67 cents a shares, missing the average analyst
estimate of 69 cents a share, according to Bloomberg data.
First-quarter sales were $440.1 million, exceeding the average
estimate of $438.4 million.       Halozyme Therapeutics Inc.  (HALO US): The San Diego-based
biopharmaceutical company said it will decrease research related
to new compounds and cut jobs by 25 percent. The company also
said it expects to incur a one-time charge in the fourth
quarter, mostly offset by reduced payroll expenses.       Myriad Genetics Inc.  (MYGN US). The Salt Lake City-based
company said its newest molecular diagnostic product, Prolaris,
accurately predicts survival with prostate cancer.  To contact the reporter on this story:
Inyoung Hwang in New York at 
 ihwang7@bloomberg.net .  To contact the editor responsible for this story:
Nick Baker at   nbaker7@bloomberg.net . 